A Study to Evaluate Lower Extremity Sleeve and Pump Device to Treat Hemiparesis
Pilot Study to Establish Use of Lower Extremity Sleeve and Sequential Compression Pump Device in Patients With Upper Extremity Weakness Post-Stroke
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: C. Joseph Yelvington, DPT
- Phone Number: 850-206-4596
- Email: Yelvington.C@mayo.edu
Study Locations
-
-
Florida
-
Saint Johns, Florida, United States, 32259
- C Joseph Yelvington
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients admitted to Mayo Clinic/Jacksonville, post-stroke with a hemiparetic upper extremity.
- Able to provide consent of participation by self-agreement.
- Patients with a hemiparetic upper extremity will be determined using the NIH Motor Arm subsection from the NIH scale and score a 1-4.
- Patients who have received thrombolytic therapeutic medicine > 13 hours (per site specific policy) will not be excluded from inclusion in this study.
- Patients who score > 13 on the BIMS to ensure intact cognition.
Exclusion Criteria:
- Inability to provide consent of participation.
- Subjects with aphasia or the inability to effectively communicate their pain consistently.
- Questionable reliability scoring < 13 on the BIMS, has an existing invasive line (PICC line, IV, AV fistula or AV graft); recent surgery or vein ligation in the involved extremity.
- Recent skin graft in the involved extremity.
- Confirmed DVT in the affected.
- Upper extremity including axillary or subclavian veins; open or active wounds or infection in the involved extremity.
- Upper extremity ischemia, gangrene, cellulitis or severe arteriosclerosis in the affected upper extremity.
- Status-post axillary lymph node dissection on the involved side; congestive heart failure (CHF) acute exacerbation; acute edema of unknown etiology in the involved upper extremity.
- Subjects with extreme deformity of the affected upper extremity.
- Subjects with an acute kidney injury.
- Subjects who are hemodynamically unstable 1,7,17.
- Patients who have received thrombolytic therapeutic medicine administered < 13 hours (per site specific policy) prior to application of SCD sleeve.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sequential Compression Device (SCD) on upper extremity
Subjects post stroke with upper extremity weakness have the SCD sleeve placed on the arm for up to 4 hours for one day only
|
Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary.
The device will inflate and deflate.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wearing Tolerance of the SCD and Sleeve on the Upper Extremity.
Time Frame: 4 hours
|
Number of subjects who answered yes to the question "Are you tolerating this sleeve"
|
4 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain With SCD Sleeve and Device
Time Frame: 4 hours
|
Total number of subjects to report No pain measured by Visual Analogue Scale (VAS) where patient identifies pain on a line between "no pain" and "worst possible pain".
|
4 hours
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nail Bed Color
Time Frame: 4 hours
|
Nail bed color will be observed and described/documented with terms of "normal", "dusky", or "bluish" in color
|
4 hours
|
|
Edema Measured in Inches of Circumference of Forearm
Time Frame: 4 hours
|
Using tape measure the weak UE forearm will be measured in inches; 5 inches distal to cubital fossa, proximal from the wrist crease.
|
4 hours
|
|
UE Strength Using Motor Arm Subsection #5 of NIH Scale
Time Frame: 4 hours
|
The limb is placed in the appropriate position: extend the arm (palm down) 90 degrees if sitting or 45 degrees if supine.
Drift is scored if the arm falls before 10 seconds.
Documenting using Scale definition: 0=No drift, 1=Drift, 2=Some effort against gravity, 3=No effort against gravity; limb falls, 4=No movement
|
4 hours
|
|
UE Sensation
Time Frame: 4 hours
|
Using cotton swab and lightly touching skin at dermatome points C2, C3, C4, C5, C6, C7, C8, T1, T2 using the International Standards for the Classification of Spinal Cord Injury Key Sensory Points documenting "Intact" or "Impaired"
|
4 hours
|
|
UE Skin Integrity
Time Frame: 4 hours
|
Prior to placement of sleeve and upon removal of sleeve during check time skin will be visually assessed and the terms "Intact" or "Impaired" will be documented.
Any new "redness", "rash", or "bruising" and "area" of arm will be documented and the need to remove sleeve at that time will be determined.
|
4 hours
|
|
UE Grip Strength
Time Frame: Baseline and at four-hours for each subject
|
Using dynamometer in pounds measures affected hand strength at baseline and at 4-hours for each subject.
This outcome measure was added approximately 1/2 way through the subject recruitment as a revision to this study to help capture subjects with hand weakness who may not have gross arm weakness (captured by Motor arm Subsection #5 outcome measure).
|
Baseline and at four-hours for each subject
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Suzanne Langley, OT, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21-009068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.